Braskem (BAK) Common Equity (2009 - 2025)

Braskem (BAK) has reported Common Equity for 17 consecutive years, with -$3.1 billion the latest figure, recorded in Q4 2025.

• Quarterly Common Equity fell 271.99% year-over-year to -$3.1 billion in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$3.1 billion (down 271.99% YoY) and the FY2025 annual result came in at -$3.1 billion, down 133.42% from the prior year.
• Common Equity declined to -$3.1 billion in Q4 2025 per BAK's latest filing, from $8.4 billion in the prior quarter.
• Over the last five years, Common Equity for BAK reached as high as $8.4 billion in Q1 2025 and fell as low as -$3.1 billion in Q4 2025.
• A 5-year average of $1.2 billion and a median of $887.4 million in 2021 frame the typical range for Common Equity.
• Annual changes were most pronounced in 2021 — Common Equity soared 295.4% — and 2025, when it sank 271.99%.
• Year by year, Common Equity stood at $1.1 billion in 2021, then increased by 4.37% to $1.2 billion in 2022, then slumped by 42.95% to $662.3 million in 2023, then tumbled by 224.23% to -$822.8 million in 2024, then plunged by 271.99% to -$3.1 billion in 2025.
• According to Business Quant data, Common Equity over the past three periods registered -$3.1 billion, $8.4 billion, and -$822.8 million for Q4 2025, Q1 2025, and Q4 2024 respectively.